Medtronic PLC $MDT Stake Lowered by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. trimmed its stake in shares of Medtronic PLC (NYSE:MDT) by 9.1% during the fourth quarter, Holdings Channel reports. The firm owned 74,371 shares of the medical technology company’s stock after selling 7,442 shares during the period. Stratos Wealth Partners LTD.’s holdings in Medtronic were worth $7,144,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in MDT. Delos Wealth Advisors LLC bought a new position in Medtronic during the 2nd quarter worth $27,000. Corundum Trust Company INC bought a new stake in Medtronic in the third quarter valued at $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic during the fourth quarter valued at $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the third quarter valued at $29,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Medtronic during the fourth quarter worth about $29,000. Institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.26% of the stock is owned by company insiders.

Medtronic Stock Performance

Shares of MDT opened at $86.61 on Friday. The firm has a market capitalization of $111.19 billion, a PE ratio of 24.12, a P/E/G ratio of 2.24 and a beta of 0.75. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average price of $94.47 and a 200 day moving average price of $96.24. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of analyst reports. Daiwa Securities Group dropped their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Truist Financial decreased their target price on shares of Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research report on Wednesday, February 18th. Citigroup assumed coverage on shares of Medtronic in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price target on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $119.00 price target on shares of Medtronic in a report on Tuesday, March 10th. Finally, CICC Research started coverage on Medtronic in a research report on Friday, January 30th. They set an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $109.85.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).